Avidity biosciences joins patient and advocacy communities in raising awareness during national muscular dystrophy awareness month

Avidity supports world duchenne awareness day, international myotonic dystrophy awareness day, fshd society walk & roll to cure fshd and global genes week in rare avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (dm1), facioscapulohumeral muscular dystrophy (fshd) and duchenne muscular dystrophy amenable to exon 44 skipping (dmd44) san diego , sept. 5, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced it is joining with patient and advocacy communities to raise awareness during national muscular dystrophy awareness month, an annual observance that takes place every september to support families who are impacted by neuromuscular diseases.
RNA Ratings Summary
RNA Quant Ranking